cancer diagnosis News
-
Southwest airlines supports families facing serious illness
Southwest Airlines and a Special Journey For John You probably wouldn’t know it by looking at him, but John, a father of three and husband to Lynn, is battling cancer. Take the stresses of everyday life: getting the kids to school on time, paying the bills, keeping the family generally happy and healthy. Then, top that with cancer. Now you’re in John’s world. It’s not ...
By 3BL Media
-
IONIQ Presents Lung Cancer Trial Results at ATS 2022
IONIQ Sciences is proud of our team members who presented our latest lung cancer clinical trial results in a poster today at the American Thoracic Society meeting in San Francisco, CA. This was a great honor to highlight our growing bioimpedance clinical evidence that continues to demonstrate the possibility of a non-invasive, low-cost, early-stage lung cancer diagnosis. Furthermore, the ...
-
Curasight A/S strengthens its institutional investor base
Curasight A/S (“Curasight” or the “Company”) has strengthened its institutional investor base as part of the company's future strategy. Arbejdernes Landsbank has today acquired 200,000 warrants from the Swedish investment company Eastbridge, which is already a strategic investor in Curasight. The transaction between Arbejdernes Landsbank and Eastbridge takes place as a ...
By Curasight
-
Seno Medical and “Know Your Lemons” Team Up For Breast Cancer Education
Seno Medical Instruments, Inc. (Seno Medical), a Texas-based medical imaging company developing breakthrough breast cancer diagnostic technology, announced an educational partnership supporting Worldwide Breast Cancer’s “Know Your Lemons” campaign starting with the Netherlands, which has one of the highest breast cancer incidence rates in the world. Through the partnership with ...
-
Rarecells, Inc. announces Appointment of Dr. Neil Gunn as New Director to the Board
Rarecells, Inc. today announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director. “We are delighted to welcome Neil as Board Director. With his broad understanding of diagnostics and the Liquid Biopsy space he is well-positioned to provide valuable perspectives and insight across a broad spectrum of topics, from ...
-
Monarch Platform Featured on Cover of Oncology Issues
The Monarch Platform was featured on the cover of the March-April 2019 issue of Oncology Issues. The journal, which is the official journal of the Association of Community Cancer Centers, was created for multidisciplinary oncology teams to provide information on a range of topics in cancer care. In the March-April issue of the journal, the Monarch Platform was featured in an article titled ...
-
Hanne Damgaard Jensen joins Curasight A/S as Chief Development Officer (CDO)
Curasight A/S (“Curasight” or the “Company”) appoints Hanne Damgaard Jensen as new Chief Development Officer. Curasight intends to expand and accelerate its clinical programs and is strengthening the organisation with Hanne Damgaard Jensen who will take on the position as Chief Development Officer (CDO) from 1 January 2022. Hanne will be responsible for all Drug ...
By Curasight
-
Rarecells, Inc. announces successful Series A funding, reaching $13 Million raised to develop Liquid Biopsy Early Cancer Detection Tests
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
-
Promaxo Announces Strategic Financing with Family Office
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced an additional $1.4 million in strategic financing from Som Tech Pty Ltd, a family office led by Krishna Bhupal. Mr. Bhupal is a well-regarded Investor in the advanced AI enabled fintech and life-sciences spaces globally. He is also a Director of GVK Power ...
-
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions, today announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software. Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by ...
-
European Radiology Profiles Seno Medical’s Ground-Breaking Breast Cancer Diagnostic Technology
Additional research appearing in the June online issue (open access) of European Radiology features the groundbreaking diagnostic breast cancer imaging technology introduced by Seno Medical Instruments™, Inc. (Seno Medical). This technology might not only help physicians better differentiate between benign and malignant breast lesions, but also discriminate between breast cancer molecular ...
-
4D Path Closes Latest Funding Round to Advance New Approach to Precise and Accelerated Cancer Diagnosis, Bringing Total to $6.4M
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology ...
By 4D Path Inc.
-
Agilent Technologies Introduces Next-Generation Sequencing Cancer Research Panels
Agilent Technologies Inc. (NYSE: A) today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia. Designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University, ClearSeq ...
-
Oncology Nurse Advisor Celebrates 10 Years
Oncology Nurse Advisor (ONA), a part of business media company Haymarket Media, Inc., is proud to celebrate their 10th anniversary this month. This milestone marks a decade of editorial excellence in the field of oncology nursing research and cancer care. Throughout the last decade ONA has evolved with the changes in nursing, starting as a print publication and transitioning over time to a ...
-
ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC). The ...
-
Exosome Services at Creative Biolabs to Accelerate Lung Cancer Research
As the incidence and mortality of lung cancer rank among the highest all over the world, lung cancer diagnostics and treatment are the most researched paper topics. Research has reported that exosomes derived from lung cancer are the most promising biomarkers for early diagnosis, prognosis, and treatment of lung cancer. With years of experience in this field, Creative Biolabs provides exosome ...
-
First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer. The study was the result of work by an international consortium, SuppresSTEM which included Crown ...
-
4D Path Announces Patented Precision Oncology Platform for Instant Biomarker Profiling and Stratification Just From H&E Biopsy or Resection Images
4D Path, a company conceived by an experienced team of scientists, clinicians and management from leading research institutions including MIT, Harvard Medical School and the University of Cambridge, has unveiled a faster, more efficient approach to cancer diagnosis and biomarker profiling with better accuracy that accelerates and democratizes precision medicine for optimized patient care and ...
By 4D Path Inc.
-
Cancer Targeted Technology Receives $2 Million Small Business Innovation (SBIR) Grant to Advance its PET Imaging Diagnostic to Clinical Trials in Prostate Cancer
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, today announced that the NIH awarded a 2-year, $2M SBIR grant to CTT to develop a new agent that will help diagnose and monitor metastatic prostate cancer. CTT1057, a positron emission tomography (PET) imaging agent, discovered by Dr. Cliff Berkman, Professor of ...
-
Kheiron Medical Technologies Launches RSViP to Help U.S. Breast Screening Programs Tackle Backlogs Worsened by COVID-19
As many as 3.9 million women in the U.S. missed their routine mammograms due to the COVID-19 pandemic,* creating a significant backlog of women to be scheduled as breast screening clinics have re-opened with reduced capacity and increased COVID-19 safety protocols. Kheiron Medical Technologies, an award-winning applied science company based in the United Kingdom, has launched RSViP™, a new ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you